EU/3/01/039

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2017 at the end of the 10-year period of market exclusivity.

On 30 May 2001, orphan designation (EU/3/01/039) was granted by the European Commission to Pharma Mar SA, Spain, for ecteinascidin 743 for the treatment of soft tissue sarcoma.

Ecteinascidin 743 in treatment of soft tissue sarcoma has been authorised in the EU as Yondelis since 17 September 2007.

This medicine is now known as trabectedin.

Key facts

Active substance
Ecteinascidin 743 (trabectedin)
Medicine name
Yondelis
Disease / condition
Treatment of soft tissue sarcoma
Date of first decision
30/05/2001
Outcome
Expired
EU designation number
EU/3/01/039

Sponsor's contact details

PharmaMar S.A.
Polígono Industrial La Mina
Av. de los Reyes 1
28770 Colmenar Viejo
Madrid
Spain
Telephone: (34-91) 846 60 00
Telefax: (34-91) 823 45 03
E-mail: pharmamar@pharmamar.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating
Average
1 rating
1 rating